GlassScriptPhysician profile
Krista N Morales
NPI 1679005326
$5,462.99
in general payments reported to CMS, 2019-2025
38 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $333 · 2021: $1,299 · 2022: $951 · 2023: $1,155 · 2024: $1,266 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $747.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $695.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.06 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $389.24 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $348.87 | 2020-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $321.54 | 2020-2024 | Mounjaro |
| Abbott Laboratories | $319.50 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $309.40 | 2020-2025 | |
| Glaxosmithkline, LLC. | $214.02 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $150.10 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $147.02 | 2022-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $141.55 | 2021 | |
| Merck Sharp & Dohme LLC | $119.84 | 2020-2025 | Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $92.53 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $70.49 | 2023 | Quviviq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $67.87 | 2022 | |
| Esperion Therapeutics, INC. | $67.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $63.95 | 2021-2025 | Rexulti |
| Seqirus USA INC | $63.02 | 2021-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Janssen Pharmaceuticals, INC | $61.26 | 2021-2022 | |
| Sanofi Pasteur INC. | $53.28 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $51.43 | 2023 | Gemtesa |
| Ucb, INC. | $46.20 | 2023 | Nayzilam |
| Exact Sciences Corporation | $45.39 | 2023-2024 | Cologuard Collection Kit |
| Exeltis, USA INC. | $35.73 | 2025 | Slynd |
| Ibsa Pharma INC. | $30.68 | 2020-2021 | |
| Axsome Therapeutics, INC. | $30.41 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $29.51 | 2021-2023 | Unithroid |
| Dynavax Technologies Corporation | $29.45 | 2023 | Heplisav-B |
| Eisai INC. | $25.25 | 2022 | |
| Tactile Systems Technology INC | $24.24 | 2023 | Flexitouch Plus, Entre Plus |
| Lundbeck LLC | $21.94 | 2024 | Rexulti |
| Allergan, INC. | $21.14 | 2020 | |
| Jazz Pharmaceuticals INC. | $20.86 | 2022 | |
| Viatris Specialty LLC | $19.39 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $18.96 | 2021 | |
| Gilead Sciences, INC. | $17.98 | 2023 | Epclusa |
| Sanofi-Aventis U.S. LLC | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.